Biosimilar Clinical Development Regulatory Pathway Planner
Regulatory and clinical development teams at biosimilar developers use this agent when designing the clinical comparability programme — including PK/PD bridging studies, immunogenicity assessments, and confirmatory efficacy trials — for a biosimilar candidate to a specific reference product, balancing evidence generation requirements against the totality-of-evidence framework applied by FDA and EMA.